Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in Advanced Solitary Fibrous Tumor
NCT03840772Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2019
- Primary completion
- Sep 2024
- Countries
- 1
- Sponsor
- Italian Sarcoma Group
- Modality
- Small Molecules
- Drugs
- eribulin
- Conditions
- solitary fibrous tumor (SFT)
01
Overview
Phase 2, open-label, single-arm trial of eribulin in solitary fibrous tumor (SFT), sponsored by Italian Sarcoma Group. Primary endpoint: Overall Response Rate at 6 weeks. Started Jul 2019; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Eribulin
Eribulin monotherapy
03
Who it enrols
Adults with molecularly proven, progressive advanced/metastatic SFT who have received 1-2 prior lines of therapy.
04
Endpoints
Primary
Overall Response Rate
Secondary
Choi Response Rate
Overall Survival
Progression-Free Survival
Clinical Benefit Rate
Adverse Events
Beyond the preview
Go deeper on NCT03840772.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840772.